Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Improving Rates of Relapse in Multiple Myeloma

January 17th 2019

Managing Heavily Pretreated R/R Multiple Myeloma

January 17th 2019

Relapsed/Refractory Multiple Myeloma: Switching Therapy

January 17th 2019

Relapsed/Refractory Multiple Myeloma: Optimal Therapy

January 17th 2019

Options for Maintenance Therapy in Multiple Myeloma

January 17th 2019

Induction Therapy Considerations in Multiple Myeloma

January 17th 2019

Treating Transplant-Ineligible Multiple Myeloma

January 17th 2019

Novel Therapies & Transplants in Multiple Myeloma

January 17th 2019

Role of MRD Assessment in Multiple Myeloma

January 17th 2019

Transplant-Eligible Multiple Myeloma: Current Treatment

January 17th 2019

High-Risk Smoldering Multiple Myeloma: Systemic Therapy

January 17th 2019

Smoldering Multiple Myeloma Treatment Considerations

January 17th 2019

Progress in the Treatment of Multiple Myeloma

January 17th 2019

MyDRUG Evaluates Targeted Agents in Multiple Myeloma

January 16th 2019

Investigators are taking a personalized approach to treating patients with multiple myeloma by introducing novel agents in combination with backbone chemotherapies, based on patients’ individual genetic profiles.

CAR T-Cell Therapy in Myeloma

January 16th 2019

Antibody-Drug Conjugates in Myeloma

January 16th 2019

Emerging Therapies in Myeloma: Selinexor

January 16th 2019

Emerging Therapies in Myeloma: Venetoclax

January 16th 2019

Monoclonal Antibodies in Relapsed-Refractory Myeloma

January 16th 2019

Proteasome Inhibitors in Relapsed-Refractory Myeloma

January 16th 2019